Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Jaguar Health Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Jaguar Health şirketinin toplam hissedar öz sermayesi $19.1M ve toplam borcu $32.9M olup, bu da borç-öz sermaye oranını 172.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $61.5M ve $42.4M dir.

Anahtar bilgiler

172.7%

Borç/özkaynak oranı

US$32.93m

Borç

Faiz karşılama oranı	n/a
Nakit	US$16.05m
Eşitlik	US$19.06m
Toplam yükümlülükler	US$42.40m
Toplam varlıklar	US$61.46m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1JA 'nin kısa vadeli varlıkları ( $40.1M ) kısa vadeli yükümlülüklerini ( $19.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: 1JA şirketinin kısa vadeli varlıkları ( $40.1M ) uzun vadeli yükümlülüklerini ( $23.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1JA 'nin net borç/öz sermaye oranı ( 88.5% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 1JA şirketinin borç/öz sermaye oranı son 5 yılda 153.9% seviyesinden 172.7% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 1JA şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 1JA un, serbest nakit akışı her yıl % 11.6 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Jaguar Health Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Jaguar Health Announces 1-For-60 Reverse Stock Split in Order to Support Compliance with Nasdaq's Listing Standards

Jaguar Health Receives Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

Jaguar Health Receives Notification Letter from The Nasdaq Stock Market LLC

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement

Recent updates

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care At American Society for Radiation Oncology Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024

Jaguar Health, Inc. Announces Issuance of New Hong Kong Patent Bolsters Ip Protection for Jaguar Health in the Treatment of Short Bowel Syndrome

Jaguar Health, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Napo Pharmaceuticals Announces Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders

Jaguar Health, Inc. Reports Phase 3 Ontarget Trial Results for Its Cancer Supportive Care Drug Crofelemer

Jaguar Health Announces 1-For-60 Reverse Stock Split in Order to Support Compliance with Nasdaq's Listing Standards

First quarter 2024 earnings released: US$0.058 loss per share (vs US$2.39 loss in 1Q 2023)

Jaguar Health, Inc., Annual General Meeting, Jun 21, 2024

Jaguar Health, Inc. to Report Q1, 2024 Results on May 14, 2024

Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration

Jaguar Health Receives Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International

Full year 2023 earnings released: US$1.79 loss per share (vs US$36.18 loss in FY 2022)

Jaguar Health, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Jaguar Health Receives Notification Letter from The Nasdaq Stock Market LLC

Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health, Inc. announced that it has received $0.06 million in funding

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.38 loss per share (vs US$8.83 loss in 3Q 2022)

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New major risk - Financial position

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$8.82 loss in 2Q 2022)

Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome

Napo Pharmaceuticals Submits Investigational New Drug Application to FDA for MicroVillus Inclusion Disease

New major risk - Market cap size

Jaguar Health, Inc., Annual General Meeting, Jul 07, 2023

Jaguar Health, Inc. Appoints Stacey Tinianov to Scientific Advisory Board

First quarter 2023 earnings released: US$2.39 loss per share (vs US$30.17 loss in 1Q 2022)

Jaguar Health Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Jaguar Health, Inc. to Report Q1, 2023 Results on May 15, 2023

Jaguar Health, Inc. announced that it has received $1.86 million in funding

Jaguar Health, Inc. announced that it expects to receive $1.86 million in funding

Full year 2022 earnings released

Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement

Jaguar Health, Inc. Provides Updates Regarding its Focus on Rare and Orphan Disease Indications in the U.S. & Europe

Jaguar Health, Inc. and Napo Pharmaceuticals Appoints Sandra M. Swain to the Scientific Advisory Board

Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (Cid) in Breast Cancer Patients

European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. announced delayed 10-Q filing

Jaguar Health, Inc. Appoints Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee

Jaguar Health, Inc. Announces Appointment of Pravin Chaturvedi as Chief Scientific Officer and Chair of the Scientific Advisory Board

Jaguar Health Regains Compliance with Nasdaq Bid Price Requirement

Jaguar Health Explores Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ Covid-19 Recovery Patients in Europe

Jaguar Health Got Letter from Nasdaq Staying Stipulation for Company to Comply with Minimum Bid Price Requirement by Dec. 23

New 90-day high: €0.40

Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Plan to Study, Develop and Commercialize Crofelemer, the Company’s Novel Proprietary Drug, for an Indication of Inflammatory Diarrhea, Initially in Europe

Revenue misses expectations

Third quarter 2020 earnings released: US$0.20 loss per share

Jaguar Health Receives Positive Nasdaq Listing Determination

New 90-day low: €0.24

Jaguar Health, Inc. Announces Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs and Quality Assurance

New 90-day low: €0.26

New 90-day low - €0.34

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin